Thiophene derivative inflicts cytotoxicity via an intrinsic apoptotic pathway on human acute lymphoblastic leukemia

Risa Mia Swain1,2, Anahi Sanchez1, Denisse A Gutierrez1

  • 1Department of Biological Sciences, The Border Biomedical Research Center, The University of Texas at El Paso, El Paso, Texas, United States of America.

Plos One
|December 21, 2023
PubMed

Insights

A novel thiophene compound, F8, shows significant anti-cancer activity against lymphoma and leukemia cell lines. This discovery highlights thiophenes as promising candidates for developing new cancer therapies.

Area of Science:

  • Medicinal Chemistry
  • Pharmacology
  • Oncology

Background:

  • Thiophene derivatives are recognized for their diverse pharmacological properties and therapeutic potential.
  • These heterocyclic compounds exhibit a wide range of activities, including anti-cancer effects, making them valuable in drug discovery.

Purpose of the Study:

  • To identify novel anti-cancer agents using High Throughput Screening (HTS).
  • To evaluate the cytotoxic effects of compounds from the ChemBridge DIVERSet Library on cancer cell lines.

Main Methods:

  • High Throughput Screening (HTS) of the ChemBridge DIVERSet Library against a lymphoma cell line.
  • Characterization of compound F8's mechanism of action, including apoptosis induction and kinase inhibition.

Main Results:

  • A novel thiophene derivative, F8, was identified with potent anti-cancer activity against lymphoma, leukemia, and other cancer cell lines.
  • Compound F8 demonstrated efficacy in the low micromolar range after 48 hours, inducing cell death via apoptosis.
  • Mechanistic studies revealed F8 induces phosphatidylserine externalization, reactive oxygen species generation, and mitochondrial depolarization.

Conclusions:

  • Compound F8 exhibits promising anti-cancer properties and warrants further investigation as a potential therapeutic agent.
  • The study validates the potential of thiophene derivatives in the development of novel anti-cancer drugs.

Related Concept Videos

The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.6K
The Extrinsic Apoptotic Pathway01:17

The Extrinsic Apoptotic Pathway

The extrinsic apoptotic pathway is initiated when extracellular death-inducing signals, such as specific cytokines, activate the death receptors expressed on the cell surface. The immune cells involved in this pathway are natural killer cells (NK cells) and cytotoxic T-lymphocytes. NK cells are critical in innate immune response, while cytotoxic T-lymphocytes are associated with adaptive immune response. These cells recognize specific receptors expressed on the altered cells and activate...
6.4K
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
923
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K